Literature DB >> 32727222

Association of serum VLDL level with hyperhomocysteinemia in hypertensive patients: A cross-sectional study.

Jian Chen2, Jing Li2, Jia Wang2, Dan Zeng2, Jian Chen2, Ying Zhang1,2, Mengyi Wu1,2, Dandan Zhang1,2, Xiuqin Hong2.   

Abstract

BACKGROUND: Increasing evidence suggests that hyperhomocysteinemia (HHcy) and hyperlipidemia have been recognized as two independent risks for cardiovascular disease. However, the association between hyperlipidemia and HHcy in hypertensive patients has not been systemically elucidated. The aim of this study was to investigate the relation between very low-density lipoprotein (VLDL) and HHcy in hypertensive patients.
METHODS: From July 2013 to March 2014, a large cross-sectional study was performed using 4012 participants from urban and rural communities in Hunan province, China. Participants underwent accurate assessment of lipid profiles, homocysteine (Hcy), anthropometric, blood pressure, and other biochemical indicators.
RESULTS: Among 1257 participants with hypertension, 626 (49.80%) were men and 631 (50.20%) were women. In total, 1081 (86.00%) of the participants were found to have HHcy, of which 559 (44.47%) were men and 522 (41.53%) were women. In the univariate analysis, the OR for patients with hypertension associated with hyperhomocysteinemia was significantly enhanced as the quartiles of the Log VLDL were increased. OR for quartile 4 was significantly higher than that for quartile 1 (OR = 3.7, 95% CI: 2.6-5.1; P< .001). Additional adjustment for the confounding variables did not reduce the ORs for the association between the Log VLDL and hypertension associated with hyperhomocysteinemia (OR = 3.8, 95% CI: 2.7-5.5; P< .001; OR = 4.3, 95% CI: 1.6-11.8; P= .004, respectively). We also conducted analyses with Log VLDL as a continuous variable. Each unit increase in the Log VLDL was associated with the 1.3-fold increased risk of hypertension associated with hyperhomocysteinemia (95% CI: 1.9-2.9; P< .001). Adjusting for Cr, TG, TC, and HDL did not affect the relationship.
CONCLUSIONS: Our data indicate that the Log VLDL concentrations appear to be an independent contributor to hypertension associated with hyperhomocysteinemia, even after adjusting for age and other covariables. The utility of the Log VLDL as a diagnostic, prognostic, and therapeutic indicator for the disease warrants further investigation. ABBREVIATIONS: HHcy: hyperhomocysteinemia; Hcy: homocysteine; VLDL: very low-density lipoprotein; CVD: cardiovascular disease; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; ALT: alanine aminotransferase; Cr: creatinine; UA: uric acid; TG: triglycerides; TC: total cholesterol; HDL: high-density lipoprotein; LDL: low-density lipoprotein; FBG: fasting blood glucose; CRP: C-reactive protein; MTHFR: methylene tetrahydrofolate reductase; NO: nitric oxide; HDL-C: high-density lipoprotein cholesterol.

Entities:  

Keywords:  Very low-density lipoprotein (VLDL); homocysteine (Hcy); hypertension associated with hyperhomocysteinemia

Mesh:

Substances:

Year:  2020        PMID: 32727222     DOI: 10.1080/10641963.2020.1797084

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  2 in total

1.  Diagnostic Value of Hcy Combined with Blood Pressure Variability Index in the Severity of Hypertension Complicated with CSVD and Its Correlation with Cognitive Function and CysC Expression.

Authors:  Qiaoling Liu; Xia Liu; Xuelian Zhang; Chen Zhou
Journal:  J Healthc Eng       Date:  2022-04-14       Impact factor: 3.822

2.  Exosome-Enriched Plasma Analysis as a Tool for the Early Detection of Hypertensive Gestations.

Authors:  Rodrigo Barbano Weingrill; Sandra Luft Paladino; Matheus Leite Ramos Souza; Eduardo Manoel Pereira; Aldilane Lays Xavier Marques; Elaine Cristina Oliveira Silva; Eduardo Jorge da Silva Fonseca; Jeferson Santana Ursulino; Thiago Mendonça Aquino; Estela Bevilacqua; Johann Urschitz; Jean Carl Silva; Alexandre Urban Borbely
Journal:  Front Physiol       Date:  2021-12-14       Impact factor: 4.566

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.